



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 24 June 2020

Re: Freedom of Information Request
Ref: 128- 2020

Thank you for your email dated the 5th June 2020, requesting information regarding patient treatment figures.

The information that you require is as follows:

Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

- 1. In the past 3 months how many metastatic melanoma patients were treated by your Trust?**

Please note that we only record stage at presentation to CCC , therefore the data provided below is based on the number of patients who presented with stage IV disease or recurrence/progression

Between 1st March 2020-31st May 2020:

- Dabrafenib = Exempt under S.40**
- Dabrafenib + Trametinib = 27 patients**
- Densoumab = 0 patients**
- Encorafenib + Binimetinib = Exempt under S.40**

- Ipilimumab = Exempt under S.40
- Ipilimumab + Nivolumab = 8 patients
- Nivolumab = 33 patients
- Pembrolizumab = 60 patients
- Trametinib = 0 patients (single agent)
- Vemurafenib = 0 patients
- Vemurafenib + Cobimetinib = 0 patients
- Other active systemic anti-cancer therapy = Exempt under S.40
- Palliative care only i.e. 1st therapeutic intervention at CCC was Specialist Palliative Care between 1st March 2020-31st May 2020 and patient presented with stage IV disease or recurrence/progression = 0 patients

2. Within your health trust how many patients are currently [within the past 3 months] being treated for metastatic Non-small-cell lung cancer (NSCLC) with the following:

Please note that we only record stage at presentation to CCC , therefore the data provided below is based on the number of patients who presented with stage IV disease or recurrence/progression

Between 1st March 2020-31st May 2020:

- Afatinib = 29 patients
- Atezolizumab monotherapy or combination = 14 patients
- Brigatinib = Exempt under S.40
- Ceretinib = 0 patients
- Crizotinib = Exempt under S.40
- Docetaxel monotherapy or combination = Exempt under S.40
- Erlotinib = 6 patients
- Gefitinib = Exempt under S.40
- Gemcitabine = Exempt under S.40
- Nitendanib + docetaxel = Exempt under S.40

- Nivolumab = Exempt under S.40
- Osimertinib = 8 patients
- Paclitaxel = Exempt under S.40
- Pembrolizumab monotherapy = 64 patients
- Pembrolizumab chemo in combination = 42 patients
- Pembrolizumab monotherapy = 64 patients (as above)
- Pemetrexed monotherapy or combination = 43 patients
- Ramucirumab = 0 patients
- Vinorelbine monotherapy or combination = Exempt under S.40
- Other active systemic anti-cancer therapy (i.e. none of the above)

Regime	Total
Alectinib	8
Cisplatin + Etoposide po&iv 3 day	Exempt under S.40
Dacomitinib	Exempt under S.40
Denosumab	21
Durvalumab	Exempt under S.40
EVEROLIMUS	Exempt under S.40
Lenvatinib/Placebo(LEAP006 Trial)	Exempt under S.40
Lorlatinib	Exempt under S.40
Octreotide	6

- Palliative care only i.e. 1st therapeutic intervention at CCC was Specialist Palliative Care between 1st March 2020-31st May 2020 and patient presented with stage IV disease or recurrence/progression = 15 patients

3. Out of the metastatic NSCLC patients currently [within the past 3 months] being treated, are you able to provide the number of patients being treated for Squamous Cell Non-small-cell lung cancer (SqNSCLC) with the following products?

Please note that we only record stage at presentation to CCC , therefore the data provided below is based on the number of patients who presented with stage IV disease or recurrence/progression

Between 1st March 2020-31st May 2020:

- **Afatinib = Exempt under S.40**
- **Atezolizumab monotherapy or combination = Exempt under S.40**
- **Brigatinib = 0 patients**
- **Ceretinib = 0 patients**
- **Crizotinib = Exempt under S.40**
- **Docetaxel monotherapy or combination = Exempt under S.40**
- **Erlotinib = 0 patients**
- **Gefitinib = 0 patients**
- **Gemcitabine = Exempt under S.40**
- **Nitendanib + docetaxel = 0 patients**
- **Nivolumab = Exempt under S.40**
- **Osimertinib = 0 patients**
- **Paclitaxel = Exempt under S.40**
- **Pembrolizumab monotherapy = 16 patients**
- **Pembrolizumab chemo in combination = Exempt under S.40**
- **Pembrolizumab monotherapy = 16 patients (as above)**
- **Pemetrexed monotherapy or combination = Exempt under S.40**
- **Ramucirumab = 0 patients**
- **Vinorelbine mono or combination = Exempt under S.40**
- **Other active systemic anti-cancer therapy = 0 patients**
- **Palliative care only i.e. 1st therapeutic intervention at CCC was Specialist Palliative Care between 1st March 2020-31st May 2020 and patient presented with stage IV disease or recurrence/progression = Exempt under S.40**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.